|
18 May 2021 |
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy
|
|
18 May 2021 |
MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors
|
|
18 May 2021 |
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
|
|
14 May 2021 |
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
|
|
14 May 2021 |
Sio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy
|
|
14 May 2021 |
Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma
|
|
14 May 2021 |
Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA
|
|
14 May 2021 |
Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
|
|
12 May 2021 |
Antion Biosciences Presents New Data on miCARTM T-cells and Multiplex Gene Engineering Technology at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
|
|
12 May 2021 |
Orchard's OTL-101 gene therapy offers potential cure for children with rare immunodeficiency
|
|
11 May 2021 |
M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24th Annual Meeting
|
|
11 May 2021 |
Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University
|
|
11 May 2021 |
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
|
|
10 May 2021 |
Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell Progenitor Product SMART 101 (ProTcell™) for AML and ALL
|
|
10 May 2021 |
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
|
|
07 May 2021 |
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
|
|
05 May 2021 |
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma
|
|
05 May 2021 |
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis
|
|
05 May 2021 |
Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)
|
|
04 May 2021 |
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
|
|
02 May 2021 |
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
|
|
30 Apr 2021 |
PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Update
|
|
30 Apr 2021 |
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
|
|
29 Apr 2021 |
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
|
|
28 Apr 2021 |
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
|
